Constellation Pharmaceuticals, Inc., the leading biopharmaceutical company focused on discovering and developing new drugs targeting epigenetic regulation of the human genome, today announced that it has raised $22 million in a Series B financing round. The financing round was led by SR One, the independent corporate healthcare venture capital arm of GlaxoSmithKline, with participation from existing investors Third Rock Ventures, The Column Group, Venrock, and Altitude Life Science Ventures. This Series B financing brings the total amount of capital raised by Constellation in the two years since its founding to $54 million.
“Our differentiated ability to develop a pipeline of drugs against a broad range of epigenetic target classes is a core feature of our business strategy, and this investment allows us to accelerate our efforts to bring these discoveries to the patient.”
Proceeds from the financing will be used to advance the development of Constellation's pipeline of compounds towards the clinic. These funds will also enable Constellation to continue applying its innovative epigenetics product engine to probe multiple classes of novel drug targets involved in chromatin regulation and disease.
"We are delighted to have SR One, a premier venture capital investor, lead the Series B round. Their investment highlights the value created since our Series A financing round and the transformative potential of epigenetics as a platform for novel therapeutics" said Mark A. Goldsmith, M.D., Ph.D., President and Chief Executive Officer of Constellation Pharmaceuticals. "Our differentiated ability to develop a pipeline of drugs against a broad range of epigenetic target classes is a core feature of our business strategy, and this investment allows us to accelerate our efforts to bring these discoveries to the patient."